Back to LRVIYLaboratorios Farmaceuticos Rovi, S.A./ADR (LRVIY)View full pipeline
Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control
Phase 2Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Allergy to Grass Pollen (Dactylis Glomerata)
View Full LandscapeDrug Information
Target Indication
Allergy to Grass Pollen (Dactylis Glomerata)
Clinical Trial
NCT01407835Last updated: 1/24/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
Treatment with nifedipinePhase 3
High Blood Pressure (& [Essential Hypertension])
Etoricoxib 90 mg + diacerein 50 mgPhase 3
Pain Management
Etoricoxib + Cyanocobalamin fixed dosePhase 3
Acute Low-back Pain
Desloratadine / Betamethasone in fixed dosePhase 3
Allergic Rhinitis
Mometasone furoatePhase 3
Mild to Moderate Persistent Allergic Rhinitis
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts